Newsletter Signup | Join Community
Combination of novel precision cancer medicines represents future direction of ovarian cancer treatment.
According to Lancet publication: PI3K - PARP inhibitor combination promising in ovarian cancer - future study warranted
There is no longer a “one-size-fits-all” approach to ovarian cancer treatment update on precision cancer medicines.
Chemotherapy and maintenance therapy options for recurrent ovarian cancer.
Survival at 2 years was 72.4% versus 40.9% with chemotherapy alone
Stay Current With Ovarian Cancer Treatment Advances & Connect with Others
Hospital and surgeon experience contribute to lower mortality rates and better outcomes for ovarian cancer.
Maintenance Therapy with Votrient Provides Benefit in Advanced Ovarian Cancer
Research suggests new immunotherapy combination treatment is promising for ovarian cancer.
Treatment of Stage III Ovarian Cancer
Looking for Long Term Survivors: https://www.massgeneral…
Great NOCC overview on maintenance therapy for ovarian cancer. …
Speak up and share your story of hope!https://mavendoctors…